Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 5, 2015, Pages 969-975

  Yamazaki, N ^a   Uhara, H ^b   Fukushima, S ^c   Uchi, H ^d   Shibagaki, N ^e   Kiyohara, Y ^f   Tsutsumida, A ^a   Namikawa, K ^a   Okuyama, R ^b   Otsuka, Y ^g   Tokudome, T ^g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g Research and Development   (Japan)

Author keywords

Dacarbazine; Immune checkpoint inhibitor; Ipilimumab; Japanese patients; Melanoma; Phase 2 study

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; DACARBAZINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IPILIMUMAB; LEVOTHYROXINE; MYCOPHENOLIC ACID; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE THYROIDITIS; BACKACHE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLITIS; CONSTIPATION; CORTICOSTEROID THERAPY; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INOPERABLE CANCER; JAPANESE (PEOPLE); LIVER FUNCTION TEST; LIVER TOXICITY; MAINTENANCE CHEMOTHERAPY; MAINTENANCE DRUG DOSE; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTATIC MELANOMA; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ERUPTIONS; ENDOCRINE DISEASE; IMMUNOLOGY; JAPAN; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; REMISSION; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; CHEMICAL AND DRUG INDUCED LIVER INJURY; CTLA-4 ANTIGEN; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84944896352     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2870-0     Document Type: Article

References (25)

1. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-1736. doi: 10.1126/science.271.5256.1734
2. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974-1982
3. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18(2):206-213
4. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206(8):1717-1725. doi: 10.1084/jem.20082492
5. Simpson TR, Li F, Montalvo-Ortiz W et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-1710. doi: 10.1084/jem.20130579
6. Bristol-Myers Squibb Company (Revised 2015) YERVOY® (ipilimumab) prescribing information. http://packageinserts.bms.com/pi/pi-yervoy.pdf. Accessed 24 June 2015
7. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(13):1290
8. Fukushima S, Kiyohara Y, Uhara H, Uchi H, Shibagaki N, Tsutsumida A, Yoshikawa S, Okuyama R, Ito Y, Yamazaki N (2015) Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. In: abstract (89) presented at the 31st Annual Meeting of the Japanese Skin Cancer Society. Osaka, Japan
9. Nokihara H, Horinouchi H, Yagishita S et al (2013) Phase 1 study of ipilimumab in combination with paclitaxel/carboplatin in patients with non-small cell lung cancer. J Thorac Oncol 8 (suppl 2):abstr P2.11-040
10. Bristol-Myers Squibb Company (2011) YERVOY® (ipilimumab) risk evaluation and mitigation strategy. https://www.hcp.yervoy.com/pages/rems.aspx. Accessed 24 June 2015
11. Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889-1894. doi: 10.1200/JCO.2014.56.2736
12. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526. doi: 10.1056/NEJMoa1104621
13. O'Day SJ, Maio M, Chiarion-Sileni V et al (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21(8):1712-1717. doi: 10.1093/annonc/mdq013
14. Schmidt H, Hamid O, Nissan A et al (2009) Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma. Eur J Cancer Suppl 7:577
15. Weber J, Thompson JA, Hamid O (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15(17):5591-5598. doi: 10.1158/1078-0432.CCR-09-1024
16. Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155-164. doi: 10.1016/S1470-2045(09)70334-1
17. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206. doi: 10.1200/JCO.2009.23.4799
18. Maio M, Grob JJ, Aamdal S et al (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33(10):1191-1196. doi: 10.1200/JCO.2014.56.6018
19. Hamid O, Schmidt H, Nissan A et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204. doi: 10.1186/1479-5876-9-204
20. Horinouchi H, Yamamoto N, Fujiwara Y et al (2015) Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs 33(4):881-889. doi: 10.1007/s10637-015-0243-5
21. Dancygier H, Runne U, Leuschner U, Milbradt R, Classen M (1983) Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings. Hepatogastroenterology 30(3):93-95
22. Frosch PJ, Czarnetzki BM, Macher E, Grundmann E, Gottschalk I (1979) Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J Cancer Res Clin Oncol 95(3):281-286
23. Greenstone MA, Dowd PM, Mikhailidis DP, Scheuer PJ (1981) Hepatic vascular lesions associated with dacarbazine treatment. Br Med J 282(6278):1744-1745
24. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368(14):1365-1366. doi: 10.1056/NEJMc1302338
25. Postow MA, Chesney J, Pavlick AC (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006-2017. doi: 10.1056/NEJMoa1414428